Long-term outcomes according to additional treatments after endoscopic resection for rectal small neuroendocrine tumors.
Jae Hwang ChaDa Hyun JungJie-Hyun KimYoung Hoon YounHyojin ParkJae Jun ParkYoo Jin UmSoo Jung ParkJae Hee CheonTae Il KimWon Ho KimHyun Jung LeePublished in: Scientific reports (2019)
The present study aimed to investigate treatment strategies determining additional treatment after endoscopic resection (ER) of rectal neuroendocrine tumor (NET)s and long-term outcomes of endoscopically resected rectal NETs. We analyzed a total of 322 patients medical records of patients who underwent ER for rectal NETs. Rectal NETs initially resected as polyps and treated with conventional endoscopic mucosal resection (EMR) were observed more frequently in the non-curative group (P = 0.041 and P = 0.012, respectively). After ER, only 44 of the 142 patients (31.0%) who did not meet the criteria for curative resection received additional salvage treatment. In multivariate analysis, lesions diagnosed via biopsies (OR, 0.096; P = 0.002) or suspected as NETs initially (OR, 0.04; P = 0.001) were less likely to undergo additional treatment. Positive lymphovascular invasion (OR 61.971; P < 0.001), positive (OR 75.993; P < 0.001), or indeterminate (OR 13.203; P = 0.001) resection margins were more likely to undergo additional treatment. Although lymph node metastasis was found in 6 patients, none experienced local or metastatic tumor recurrence during the median follow-up of 40.49 months. Long-term outcomes after ER for rectal NETs were excellent. The prognosis showed favorable outcomes regardless of whether patients receive additional salvage treatments.
Keyphrases
- end stage renal disease
- prognostic factors
- newly diagnosed
- ejection fraction
- chronic kidney disease
- lymph node metastasis
- rectal cancer
- squamous cell carcinoma
- peritoneal dialysis
- type diabetes
- ultrasound guided
- patient reported outcomes
- lymph node
- pulmonary embolism
- weight loss
- estrogen receptor
- insulin resistance
- data analysis
- replacement therapy
- cell migration